Anbogen Therapeutics is a clinical-stage biotechnology company based in Taipei, Taiwan, focused on developing precision anti-cancer therapies. The company was founded by Dr. Joe Shih and is committed to R&D innovations to improve cancer patient outcomes. Two of its investigational drugs, ABT-101 for NSCLC with HER2 exon20 insertion mutations and ABT-301 (to be combined with immune checkpoint inhibitors) are currently in human clinical trials. Anbogen raised funding in a Series A+ to advance its pipeline. The company intends to use the proceeds to support a Phase II clinical trial of ABT-301 in combination with PD-1 inhibitors for microsatellite stable (MSS) metastatic colorectal cancer. The company highlights MSS metastatic colorectal cancer as comprising about 95% of the metastatic colorectal cancer population that does not benefit from immune checkpoint inhibitors. Anbogen Therapeutics is a clinical-stage biotech headquartered in Taipei, Taiwan, focused on developing precision anti-cancer small molecules. The company’s two lead candidates are ABT-101, a HER2-targeting tyrosine kinase inhibitor, and ABT-301, a small molecule that potentiates immune checkpoint inhibitors. ABT-101 has shown substantial potency and safety in preclinical studies and a phase 1b trial, with superior selectivity against HER2 exon 20 insertion mutations. ABT-301 completed a phase 1 trial and demonstrated superior safety and pharmacokinetic profiles versus similar marketed drugs; repeated animal studies show strong synergy with anti-PD‑1/PD‑L1 therapies, including activity in MSS colorectal cancer models and modulation of the tumor microenvironment to increase killer T cell infiltration. The company says clinical signs of safety and benefit have been observed in non-small cell lung cancer patients, including sustained tumor suppression in patients previously resistant to Enhertu. Led by CEO Dr. Tsu-An Hsu and General Manager Joe Hsueh, Anbogen positions its programs to address national medical needs and accelerate development toward improved cancer treatments.

Total raised

$20M

Funding rounds

2

Latest round

Series A

Latest activity

Jul 2024